The company held the second session of the 11th board of directors and the second session of the 10th board of supervisors to examine and approve the annual work report and other relevant proposals.
Release time:
2021-05-06
News from our newspaper # February 24 , Chairman Jiang Xiaomeng of the Group Company presided over the meeting of the 11th Board of Directors of the Company, deliberating and passing 2020 Annual Board of Directors Report, 2020 General Manager Business Report, 2020 Annual Report and other 15 related reports and proposals. The 10th 2 Supervisory Board of the Company was also held on the same day.
Due to the new coronary pneumonia epidemic, the national cement industry was greatly affected in the short term, but the overall operation of the industry was stable throughout the year. 2020 , the company made new progress in the construction of cement projects. The off-site technological transformation project (with waste heat power generation) of the new dry cement production line with a daily output of 4500 tons of clinker in Huangping, Guizhou was completed and put into trial production in 9 . The production license was successfully obtained during the year. All production and operation indexes of the production line basically reached the expected targets. The cement enterprises under the company actively carry out benchmarking management and standardized management, continuously promote the "three reductions and three improvements" activities, steadily implement various technological transformation work, and continuously improve the production efficiency of enterprises while strictly controlling production costs. A total of ,526 tons of cement and clinker were sold throughout the year. Daye Peak has implemented more than 10 technical reforms such as the technical reform of the newly added raw meal online analyzer, the technical reform of the grate cooler, the transformation of the cement mill system, and the transformation of the waste heat power generation DCS . The quality of raw meal has been significantly improved and the standard coal consumption per ton of clinker has decreased. Yunnan Peak has completed the technical renovation of grate cooler, preheater and other equipment, effectively increasing the output of rotary kiln. In addition, the company integrated part of the equity participation in the cement business and sold the equity of Guangxi Huying; participated in the major asset reorganization of Tianshan shares with the equity of Southern Cement held by the company, further optimizing the asset allocation structure.
2020, the reform of the pharmaceutical industry continued to increase, the industry pattern further changed. Jianfeng Pharmaceutical and its subsidiaries further strengthened product research and development and innovation. Paroxetine Hydrochloride Tablets passed the consistency evaluation and obtained the production approval documents of esomeprazole sodium raw materials and injections. Subsidiaries Jianfeng Yien and Zhejiang Erying respectively obtained the clinical approval documents of Class I anti-tumor new drug JFAN-1001 and Class III new drug acetaminophen suppository. Jianfeng Pharmaceutical and its subsidiaries have made progress in a number of technological transformation and engineering construction. The annual output of 20 .6 billion solid preparations (internationalization) project in Jinxi Production Base of Jianfeng Pharmaceutical has been included in the key technological transformation project of Jinhua City in 2020 . At present, the civil work of the main project has been basically completed, and equipment installation and debugging, quality system introduction and verification are underway. New North Card and New Peak North Card have fully implemented technical transformation, on the basis of its existing pesticides and pharmaceutical intermediates, it will be upgraded to become a comprehensive R & D and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations of Jianfeng Pharmaceutical. Peak Pharmaceutical is also actively exploring new marketing models, further improving the commission-based marketing model and incentive assessment system.
In addition, under continued market regulation, the image of the health care industry and consumer trust have recovered, and under the influence of the new crown epidemic, national health care awareness has been growing and demand for health care products has gradually recovered. Subsidiaries Jianfeng Health, Tianjin Jianfeng Natural Products and Tianjin Flanders have all passed the national high-tech enterprise certification; Jianfeng Health has newly added health food registration approval documents, realizing the customized sales and product development of multiple functional foods; Tianjin Jianfeng Natural Products has updated and optimized the product technology, effectively reducing the production cost; tianjin Flanders has obtained production licenses for special dietary foods (nutritional supplements for pregnant women and lactating mothers) and convenience foods (instant cereals), realizing product transformation. Jianfeng International Trade readjusted the layout of the warehouse base, completed the construction of two new logistics warehouses, further improved the land utilization rate and increased the operation and storage area, and made full use of the storage and transportation advantages of Jinhua South Station to effectively improve the storage and operation capacity. Peak cable through the adjustment of product structure, pay attention to the maintenance and training of large customers, the annual production and sales, profits have increased year-on-year. On the day of
, the company also held the2 meeting of the 10th board of supervisors, deliberating and approving 5 related reports and proposals such as the company's 2020 annual board of supervisors report, 2020 annual financial final accounts report, 2020 annual profit distribution plan, etc. (residual fruit)
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page